Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Calluna Pharma logo — Developing first-in-class therapies designed to defeat chron...

Calluna Pharma

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source.

Founded 2024 Norway Norway 27 employees Series A Total: $75.00M Biotechnology, Pharmaceutical

General Information

Company Name Calluna Pharma
Founded Year 2024
Location Norway Norway
Employees 27
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Business Model B2B, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Calluna Pharma. To contact Calluna Pharma, visit callunapharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Calluna Pharma compare?

A PDF of Calluna Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Calluna Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Calluna Pharma

Calluna Pharma, founded in 2024, is a clinical-stage biotech company based in Norway. The company focuses on developing first-in-class therapies to address chronic inflammation and fibrosis by targeting the upstream amplifiers of diseases. This innovative approach could potentially yield treatments applicable to numerous therapeutic areas, especially where existing options fall short.

Their commitment to advancing the field is reflected in their use of immunology to push boundaries and develop treatments that can significantly improve patient outcomes. Operating within the Biotechnology and Pharmaceutical industries, Calluna Pharma aspires to challenge the status quo with real-world solutions for serious diseases.

The company recently secured a €75.00M Series A investment on 01 January 2024, with substantial backing from prominent investors including Forbion, Investinor, Sarsia, and NVEST VENTURE. This funding underscores strong investor confidence in their cutting-edge therapeutic approach and potential market impact.

Business keywords: chronic inflammation, fibrosis, therapies, clinical stage, biotech, upstream amplifiers, immunology, patient outcomes, selective antibodies, immunological diseases, novel therapeutics, unmet clinical needs, disease spectrum, therapeutic pipeline, biopharmaceutical innovation

Services & Products

development of first-in-class clinical-stage antibodies
research and development in fibrosis and inflammation
pharmaceutical innovation

Target Customers

patients with high unmet medical needs related to fibrosis and inflammation healthcare providers medical institutions

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A €75.00M 4
Forbion Investinor Sarsia
Forbion, Investinor +2
01 Jan 2024

Calluna Pharma Alternatives & Competitors

View All Alternatives
Calluna Pharma vs
KeifeRx
KeifeRx United States

KeifeRx is a biopharmaceutical company finding disease-modifying treatments for neurodegenerative di...

Series A
7 employees
Biopharma, Biotechnology
Compare Calluna Pharma vs KeifeRx
Calluna Pharma vs
NewAmsterdam Pharma Corporation
NewAmsterdam Pharma Corporation United States

NewAmsterdam Pharma Corporation is a clinical-stage biopharma company creating therapies for cardiom...

IPO
102 employees
Biotechnology, Life Sciences
Compare Calluna Pharma vs NewAmsterdam Pharma Corporation
Calluna Pharma vs
Lumos Pharma
Lumos Pharma United States

Transforming Lives with Rare Focus

Series B
47 employees
Biopharma, Biotechnology
Also compare with: Calluna Pharma vs Yuanyin Bio Yuanyin Bio View all alternatives

FAQ About Calluna Pharma

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source.
Calluna Pharma was founded in 2024.
Calluna Pharma is headquartered in Norway.
Calluna Pharma operates in Biotechnology and Pharmaceutical. Its work centres on chronic inflammation, fibrosis, therapies and clinical stage. Its customers include patients with high unmet medical needs related to fibrosis and inflammation, healthcare providers and medical institutions.
Calluna Pharma has a B2B and B2D business model. Its revenue comes from Licensing and Product Sales.
Calluna Pharma has approximately 27 employees.
Calluna Pharma has completed 1 funding round, raising a total of $75.00M. The latest funding stage is Series A.
Calluna Pharma offers: development of first-in-class clinical-stage antibodies, research and development in fibrosis and inflammation, pharmaceutical innovation.
Top alternatives and competitors to Calluna Pharma include KeifeRx, NewAmsterdam Pharma Corporation, Lumos Pharma, AusperBio, Ultragenyx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Calluna Pharma and KeifeRx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Calluna Pharma, https://bouncewatch.com/company/calluna-pharma, updated 18 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes